InvestSMART

Pacific Edge Limited (ASX:PEB)

ALERT: Price-sensitive ASX Announcement for PEB
Current share price for PEB : $0.210 -0.03 (-12.50%)+
Release
14 Jul 2026 7:30AM
Price at Release
$0.240
Full Release
download
Summary
Pacific Edge Limited's Q1 27 update highlights a stable commercial throughput despite a reduced sales headcount as part of capital preservation efforts. The company's sales force efficiency improved significantly, aided by reduced headcount and increased test volumes from partnerships such as Kaiser Permanente. The operating expenses were carefully managed, reducing by 9.5% compared to the previous fiscal year. Despite a challenging environment with Medicare coverage impacts, APAC operations showed growth, with overall financial metrics indicating a strategic shift towards stabilizing cash flow and preparing for anticipated Medicare reimbursement for key tests. The company aims to leverage upcoming commercial and clinical milestones to unlock further value.
Key Points
  • Commercial throughput held steady for three consecutive quarters despite reducing sales headcount.
  • Sales force efficiency increased significantly from 440 to 659 tests per FTE due to headcount reduction and increased volumes from Kaiser Permanente.
  • Shift in product mix from Detect to Triage in Q1 26.
  • FY26 saw a net loss increase by 19.5% primarily due to Medicare non-coverage determination.
  • APAC operations showed steady growth with a 7.9% increase in total tests.
  • Operating expenses saw a reduction of 9.5% through diligent management.
  • Future outlook includes unlocking value through upcoming commercial, clinical, and innovation milestones.
  • Draft LCD proposes Medicare reimbursement for Triage and Triage Plus tests, effective by January 2027.
  • Cash flow improved with reduction in monthly cash burn by 27.7% in 2H 26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.